We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: KromaHealth Kit from Group K Diagnostics (Photo courtesy of Group K Diagnostics)
Image: KromaHealth Kit from Group K Diagnostics (Photo courtesy of Group K Diagnostics)

Group K Diagnostics (GKD; Philadelphia, PA, USA) demonstrated its KromaHealth Kit that enables point-of-care testing and fast results across a suite of various diagnostics at AACC 2021.

Every year, the global laboratory medicine community comes together at AACC to collaborate and create system-wide changes that improve patient outcomes and enhance the quality of life for all. The exhibition provides a platform to connect with the industry leaders making ground-breaking advancements in laboratory medicine, including clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, and lab management.

At this year’s AACC, GKD demonstrated its KromaHealth Kit which consists of a single-platform, versatile, point-of-care device, known as KromaHealth, paired with a mobile application used to read the test results, known as KromaViewer. Depending on the test, a user needs to simply place a few drops of blood, serum or urine on the device's testing sites to induce a color change that is translated into a clear diagnosis through an image processing algorithm. The process is simple and can be done in the physician's office with results provided before the patient leaves the physician’s office. The device is for investigational use only and its performance characteristics have not been established

GKD is currently developing the GKD Analytics Manager which is a dashboard for health system operators and researchers to monitor testing operations and collect anonymized results to analyze population health, disease management and compliance. GKD is also developing the MyGKD app which gives patients the ability view and track test results over time on their mobile phones. With this convenient access to their diagnostics, patients can own their results and be engaged in the effectiveness of their care.

Related Links:
Group K Diagnostics

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.